MX2015010765A - Metodos y composiciones para tratar y prevenir una lesion intestinal y enfermedades relacionadas a la disfuncion de las uniones estrechas. - Google Patents
Metodos y composiciones para tratar y prevenir una lesion intestinal y enfermedades relacionadas a la disfuncion de las uniones estrechas.Info
- Publication number
- MX2015010765A MX2015010765A MX2015010765A MX2015010765A MX2015010765A MX 2015010765 A MX2015010765 A MX 2015010765A MX 2015010765 A MX2015010765 A MX 2015010765A MX 2015010765 A MX2015010765 A MX 2015010765A MX 2015010765 A MX2015010765 A MX 2015010765A
- Authority
- MX
- Mexico
- Prior art keywords
- intestinal injury
- exercise
- treating
- nsaid
- glycerophosphate
- Prior art date
Links
- 208000037817 intestinal injury Diseases 0.000 title abstract 8
- 239000000203 mixture Substances 0.000 title abstract 4
- 102000000591 Tight Junction Proteins Human genes 0.000 title abstract 3
- 108010002321 Tight Junction Proteins Proteins 0.000 title abstract 3
- 210000001578 tight junction Anatomy 0.000 title abstract 3
- 230000004064 dysfunction Effects 0.000 title abstract 2
- 208000028774 intestinal disease Diseases 0.000 title 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 5
- 239000001736 Calcium glycerylphosphate Substances 0.000 abstract 2
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 abstract 2
- 229940095618 calcium glycerophosphate Drugs 0.000 abstract 2
- 235000019299 calcium glycerylphosphate Nutrition 0.000 abstract 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 125000003128 glycerophosphate group Chemical group 0.000 abstract 1
- 150000002315 glycerophosphates Chemical class 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Abstract
Se describen métodos y composiciones para tratar y prevenir lesión intestinal; en particular se describen métodos y composiciones revestidas entéricas de liberación retrasada de sales de glicerofosfato para tratar y prevenir una lesión intestinal, como lesión intestinal inducida por el ejercicio, lesión intestinal inducida o agravada por ingestión de fármacos antiinflamatorios no esteroideos (NSAID) o lesión intestinal inducida por el ejercicio agravada por un NSAID; la administración oral o nasal de una cantidad terapéuticamente efectiva de una sal de glicerofosfato, particularmente glicerofosfato de calcio, a un sujeto que realiza un ejercicio, particularmente un sujeto que realiza ejercicio e ingiere un NSAID para el tratamiento o prevención de dolor musculoesquelético resultado del ejercicio, reduce la lesión intestinal inducida por el ejercicio, particularmente lesión intestinal inducida por el ejercicio agravada por el NSAID; también se describe un método para incrementar la integridad de la unión estrecha en un sujeto que lo necesite; el método involucra administrar al sujeto una composición que comprende una cantidad efectiva de glicerofosfato, como un glicerofosfato de calcio; también se describe un método para tratar o prevenir una enfermedad relacionada con la disfunción de unión estrecha, como una enfermedad inflamatoria o un cáncer.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361766976P | 2013-02-20 | 2013-02-20 | |
| US201361827080P | 2013-05-24 | 2013-05-24 | |
| US201361897672P | 2013-10-30 | 2013-10-30 | |
| PCT/US2014/017408 WO2014130678A2 (en) | 2013-02-20 | 2014-02-20 | Methods and compositions of treating and preventing intestinal injury and diseases related to tight junction dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015010765A true MX2015010765A (es) | 2016-05-09 |
Family
ID=50240015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015010765A MX2015010765A (es) | 2013-02-20 | 2014-02-20 | Metodos y composiciones para tratar y prevenir una lesion intestinal y enfermedades relacionadas a la disfuncion de las uniones estrechas. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20150374725A1 (es) |
| EP (1) | EP2958567A2 (es) |
| JP (1) | JP2016509059A (es) |
| KR (1) | KR20150141943A (es) |
| CN (1) | CN105163740A (es) |
| AU (1) | AU2014218903A1 (es) |
| HK (1) | HK1219868A1 (es) |
| MX (1) | MX2015010765A (es) |
| WO (1) | WO2014130678A2 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201618783A (zh) | 2014-08-07 | 2016-06-01 | 艾森塔製藥公司 | 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2993837A (en) * | 1959-07-13 | 1961-07-25 | Frosst & Co Charles E | Enteric coated tablets |
| US5665415A (en) | 1995-07-26 | 1997-09-09 | Akpharma Inc. | Composition and method for increasing the pH of acid foods |
| US20020099037A1 (en) * | 2001-01-19 | 2002-07-25 | Akpharma, Inc. | Method for alleviating syndromes and conditions of discomfort of the mammalian intestinal and genito-urinary tracts |
| US7402323B2 (en) | 2002-08-21 | 2008-07-22 | Akpharma, Inc. | Compositions and methods for treating skin conditions |
| KR20060105735A (ko) * | 2003-07-04 | 2006-10-11 | 니코메드 덴마크 에이피에스 | 경구용 부갑상선 호르몬 함유 약학 조성물 |
| AR045068A1 (es) * | 2003-07-23 | 2005-10-12 | Univ Missouri | Formulacion de liberacion inmediata de composiciones farmaceuticas |
| US20100041630A1 (en) * | 2007-02-14 | 2010-02-18 | Prelief Inc. | Methods for Treating or Preventing Inflammation Using a Glycerophosphate Salt |
| WO2008112561A1 (en) * | 2007-03-09 | 2008-09-18 | Pfantastic Medical Research Institute, Llc | Combination therapy for alleviating pain-related conditions |
| WO2009029692A1 (en) * | 2007-08-30 | 2009-03-05 | Prelief Inc. | Methods for improving healing of an oral lesion using a glycerophosphate salt |
| WO2009052489A2 (en) * | 2007-10-19 | 2009-04-23 | Alba Therapeutics Corporation | Novel inhibitors of mammalian tight junction opening |
-
2014
- 2014-02-20 KR KR1020157025637A patent/KR20150141943A/ko not_active Application Discontinuation
- 2014-02-20 WO PCT/US2014/017408 patent/WO2014130678A2/en active Application Filing
- 2014-02-20 EP EP14709068.2A patent/EP2958567A2/en not_active Withdrawn
- 2014-02-20 CN CN201480009770.0A patent/CN105163740A/zh active Pending
- 2014-02-20 US US14/768,373 patent/US20150374725A1/en not_active Abandoned
- 2014-02-20 AU AU2014218903A patent/AU2014218903A1/en not_active Abandoned
- 2014-02-20 JP JP2015558954A patent/JP2016509059A/ja not_active Abandoned
- 2014-02-20 MX MX2015010765A patent/MX2015010765A/es unknown
-
2016
- 2016-06-03 HK HK16106374.5A patent/HK1219868A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014218903A1 (en) | 2015-09-17 |
| WO2014130678A2 (en) | 2014-08-28 |
| EP2958567A2 (en) | 2015-12-30 |
| HK1219868A1 (zh) | 2017-04-21 |
| JP2016509059A (ja) | 2016-03-24 |
| KR20150141943A (ko) | 2015-12-21 |
| US20150374725A1 (en) | 2015-12-31 |
| CN105163740A (zh) | 2015-12-16 |
| WO2014130678A3 (en) | 2014-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201790124A1 (ru) | Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения | |
| MX2018003331A (es) | Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados. | |
| JP2015038135A5 (es) | ||
| EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| MY176246A (en) | Compositions for oral administration of zoledronic acid or related compounds for treating disease | |
| EA201491606A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| MX2018006247A (es) | Metodos para tratar la enfermedad de alzheimer y trastornos relacionados. | |
| PH12017500444A1 (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| EA200870469A1 (ru) | Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| EA201270071A1 (ru) | Способ лечения пациента, нуждающегося в аспириновой терапии | |
| BR112013021566A2 (pt) | composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula | |
| WO2016090024A3 (en) | Combination therapy for treatment of cancer | |
| BR112013000190A2 (pt) | formas de dosagem de retenção gástrica compreendendo um análogo de gaba e um opioide | |
| EA201691555A1 (ru) | Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени | |
| MX359770B (es) | Terapia de combinacion de un inhibidor de mek e inhibidor de igf1r. | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| EA201792530A1 (ru) | Пероральная композиция целекоксиба для лечения боли | |
| MX2020007971A (es) | Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar. | |
| AR092104A1 (es) | LAQUINIMOD EN EL TRATAMIENTO DE LOS TRASTORNOS MEDIADOS POR EL ACIDO g-AMINOBUTIRICO (GABA) | |
| MX2015010765A (es) | Metodos y composiciones para tratar y prevenir una lesion intestinal y enfermedades relacionadas a la disfuncion de las uniones estrechas. | |
| TW201129361A (en) | Methods for treating pain | |
| TR201819662T4 (tr) | Çocukluk çağı hipertansiyon tedavisinde kullanılan enalapril içeren ağızda dağılan film bileşimi. |